Boston Scientific (BSX) has been the "gang who couldn’t shot straight" of the medical device business for some time. It spent far too much money to buy another medical company, Guidant. For…
The mid-month reports on short interest in NYSE shares showed that many short sellers moved out of big financial stocks but made large bets against airlines and auto companies. With the prices…
According to Reuters, earnings from Texas Instruments (TXN) disappointed investors and the company issued a weak forecast. Reuters report that RBS (RBS) will raise $24 billion to help the bank which is…
The short interest in NYSE stocks hit a record for the March 31 period. The number compare to those on March 14. Shares short in banks and brokerages began to drop. Short…
"The current financial crisis is the most serious since the second world war, and perhaps since the Great Depression."–The London Observer, March 23, 2008 Many investors find it hard to believe that…
Wall St. has gone from hating financial firms with bad balance sheets to hating all companies with big pools of debt. With the crisis which has evolved over the last few day,…
The government is fond of using taxes and tax benefits to change behavior. Put a big tax on cigarettes and people will smoke less. Put a "gas guzzler" tax on big cars…
The bad days never seem to end at Boston Scientific (NYSE: BSX). The company has a heavy debt load from a bad acquisition of Guidant. The BSX stent business has been hurt…
Douglas A. McIntyre According to Reuters, Microsoft (MSFT) would borrow some of the money for a purchase of Yahoo! (YHOO). Reuters writes that Toyota’s (TM) net grew 7.5% on emerging market growth. Reuters writes that…
On Tuesday morning, we’ll get to see earnings out of Boston Scientific Corp. (NYSE:BSX). The estimates from First Call for the medical device developer are $0.09 EPS on $2.13 billion in revenues. …
Douglas A. McIntyre Medtronic, Inc. (NYSE: MDT) has just announced that it has received formal approval from the FDA to market its Endeavor Zotarolimus-Eluting Coronary Stent System for the treatment of coronary artery disease. This…
These are not at all the only analyst calls that 247WallSt.com is looking at today in an active negative market, but these are 10 of the more influential calls that may stand…
It seems that all of a sudden corporations are deciding to do the right thing by getting rid CEO’s that have put the companies and shareholders in untenable positions. We called CEO…
2007 has been a volatile year in the stock market, but there are many key technology CEO’s who just aren’t making a passing grade. 247WallSt.com has issued a brief list of some…
For Boston Scientific (BSX) the news gets worse every day. The FDA says it will set up new guidelines for testing stents, which is one of BSX’s largest businesses. According to The…
Douglas A. McIntyre 